The Fly | PAVM

Pioneering Early Cancer Detection: Pavmed's lead products, EsoGuard and EsoCheck, address a critical unmet need for early, non-invasive screening of esophageal adenocarcinoma, a cancer often diagnosed at late, incurable stages.

Minimally Invasive Diagnostic Technology: The EsoCheck device offers a comfortable, swallowable capsule for collecting esophageal cells, which are then analyzed by the EsoGuard DNA test, providing a less invasive alternative to traditional endoscopy for high-risk patients.

Expedited Regulatory Pathway: EsoGuard has received FDA Breakthrough Device designation, which can accelerate its regulatory review process and potentially streamline its path to Medicare coverage and reimbursement.

Regulatory Approval Delays: Regulatory bodies like the FDA may delay or deny approval for Pavmed's devices, such as the EsoGuard and EsoCheck, hindering market entry and revenue generation.

Commercialization Challenges: Successfully launching and achieving widespread market adoption for new medical devices is complex, requiring significant sales and marketing efforts, physician training, and favorable reimbursement policies which may not materialize.

Capital Requirements: Pavmed is a development-stage company that may require substantial additional capital to fund clinical trials, regulatory submissions, manufacturing, and commercialization activities, potentially leading to dilution for existing shareholders.

Charts

Regulatory Approval Delays: Regulatory bodies like the FDA may delay or deny approval for Pavmed's devices, such as the EsoGuard and EsoCheck, hindering market entry and revenue generation.